Abstract
IntroductionDiscrimination between (high-grade) brain tumor recurrence and radiation necrosis (RN) remains a diagnostic challenge because both entities have similar imaging characteristics on conventional magnetic resonance imaging (MRI). Metabolic imaging, such as positron emission tomography (PET) could overcome this diagnostic dilemma. In this study, we investigated the potential of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG), O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET), and [18F]-Fluoromethyl-dimethyl-2-hydroxyethylammonium (18F-fluoromethylcholine, 18F-FCho) PET in discriminating high-grade tumor from RN. MethodsWe developed a glioblastoma (GB) rat model by inoculating F98 GB cells into the right frontal region. Induction of RN was achieved by irradiating the right frontal region with 60Gy using three arcs with a beam aperture of 3×3mm (n=3). Dynamic PET imaging with 18F-FDG, 18F-FET, and 18F-FCho, as well as 18F-FDG PET at a delayed time interval (240min postinjection), was acquired. ResultsMRI revealed contrast-enhancing tumors at 15days after inoculation (n=4) and contrast-enhancing RN lesions 5–6months postirradiation (n=3). On 18F-FDG PET, the mean lesion-to-normal ratio (LNRmean) was significantly higher in GB than in RN (p=0.034). The difference in the LNRmean between tumors and RN was higher on the late 18F-FDG PET images than on the PET images reconstructed from the last time frame of the dynamic acquisition (this is at a conventional time interval). LNRs obtained from 18F-FCho PET were not significantly different between GB and RN (p=1.000). On 18F-FET PET, the LNRmean was significantly higher in GB compared to RN (p=0.034). ConclusionsUnlike 18F-FCho, 18F-FDG and 18F-FET PET were effective in discriminating GB from RN. Interestingly, in the case of 18F-FDG, delayed PET seems particularly useful. Advances in knowledge and implications for patient careOur results suggest that (delayed) 18F-FDG and 18F-FET PET can be used to discriminate GB (recurrence) from RN. Confirmation of these results in clinical studies is needed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
